Cobra Biologics and Algeta ASA have entered a new contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate (TTC) program focusing on the development of an undisclosed monoclonal antibody targeting hematological cancer cells.   Cobra will provide cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP production, as well as stability studies.   Peter Coleman, chief executive officer of Cobra B...